Therapeutic inhibition of the renin angiotensin aldosterone system

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 6, 2009, Pages 753-759

  Laight, David W ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Aldosterone; Angiotensin converting enzyme; Angiotensin II; Cardiovascular disease; Renin; Vasopressin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; RENIN INHIBITOR; VASOPRESSIN;

CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DRUG INHIBITION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 67649305225     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903008536     Document Type: Review

References (84)

1. Cohn JN. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv Therap 2007;24:1290-1304 (Pubitemid 351618138)
2. Battle D, Soler MJ, Wysocki J. New aspects of the renin-angiotensin- aldosterone system: angiotensin converting enzyme 2 - a potential target for treatment of hypertension and diabetic nephropathy. Curr Opin Nephrol Hypertens 2008;17:250-257
3. Contreras F, De La Parte MA, Cabrera J, et al. Functional aspects of the renin-angiotensin-aldosterone system amd angiotensin II receptor AT1 blockers in arterial hypertension. Int Congress Series 2002;1237:87-98
4. Gring CN, Francis GS. A hard look at angiotensin receptor blockers in heart failure. J Am Coll Cardiol 2004;44:1841-1846 (Pubitemid 39424085)
5. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-128 (Pubitemid 43902687)
6. Ferrario CM, Strawn WB. Targeting the RAAS for the treatment of atherosclerosis. Drug Discov Today 2005;2:221-229 (Pubitemid 41488155)
7. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008;29:367-374
8. Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004;47:116-130 (Pubitemid 39600946)
9. Ahmad J. Renin-angiotensin system blockade in diabetic nephropathy. Diabetes Metabolism Syndrome. Clin Res Rev 2008;2:135-158 (Pubitemid 351634281)
10. Ruilope LM. Angiotensin receptor blockers: RAAS blockade and renoprotection. Curr Med Res Opin 2008;24:1285-1293 (Pubitemid 351751955)
11. Patton KP, Page RL. Pharmacological therapy of atrial fibrillation. Expert Opin Investig Drugs 2007;16:169-179 (Pubitemid 46206631)
12. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. J Am Coll Cardiol 2005;45:1832-1839 (Pubitemid 40789940)
13. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. J Am Coll Cardiol 2005;46:821-826
14. Seed A, Gardner R, McMurray J, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Failure 2007;9:1120-1127 (Pubitemid 47633316)
15. Cheng JWM. Aliskiren: renin inhibitor for hypertension management. Clin Therap 2008;30:31-47 (Pubitemid 351834725)
16. Siragy H, Huang J, Lieb DC. The development of the direct inhibitor aliskiren: treating hypertension and beyond. Expert Opin Emerg Drugs 2008;13:417-430
17. Sureshkumar KK, Vasudevan S, Marcus RJ, et al. Aliskiren: clinical experience and future perspectives of renin inhibition. Expert Opin Pharmacother 2008;9:825-837 (Pubitemid 351566196)
18. Nguyen G, Contrepas A. The (pro)renin receptors. J Mol Med 2008;86:643-646
19. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(8 Suppl B):9-20 (Pubitemid 350130888)
20. Bader M, Ganten D. Update on tissue-angiotensin systems. J Mol Med 2008;86:615-621
21. Krop M, Danser AHJ. Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. Curr Hypertens Rep 2008;10:112-118
22. Wolf G. Novel aspects of the renin-angiotensin-aldosterone-system. Front Biosci 2008;4993-5005 (Pubitemid 351599653)
23. Ikeda M, Arakawa K. Kininogenase activity of tonin. Hypertens 1984;6:222-228 (Pubitemid 14111491)
24. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Int Med 2008;264:224-236
25. Arinzon ZH, Lehman YA. Cilazapril-induced SIADH. J Am Geriatrics Soc 2001;49:1735
26. Shaikh ZH, Taylor HC, Maroo PV, Llerena LA. Syndrome of inappropriate antidiuretic hormone secretion associated with lisinopril. Ann Pharmacother 2000;34:176-179
27. Aulakh GK, Sodhi RK, Singh M. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators. Life Sci 2007;81:615-639 (Pubitemid 47271905)
28. Wallinder C, Botros M, Rosenstrom U, et al. Selective angiotensin II AT2 receptor agonists: benzamide structure-activity relationships. Bioorg Med Chem 2008;16:6841-6849
29. Wu X, Wan Y, Mahalingam AK, et al. Selective angiotensin II AT receptor agonists: arylbenzylimidazole structure-activity relationships. J Med Chem 2006;49:7160-7166 (Pubitemid 44886001)
30. Keidar S, Kaplan M, Gamliel-Lazarovich A. ACE2 of the heart: From angiotensin I to angiotensin (1-7). Cardiovasc Res 2007;73:463-469
31. Varagic J, Trask AJ, Jessup JA. New angiotensins. J Mol Med 2008;86:663-671
32. Iusuf D, Henning RH, Van Gilst W, Roks AJM. Angiotensin-(1-7): Pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 2008;585:303-312
33. Wiemar G, Dobrucki LW, Louka FR, et al. AVE0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertens 2002;40:847-852
34. Ebermann L, Spillman F, Sidiropoulos M, et al. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. Eur J Pharmacol 2008;590:276-280
35. Ferreira AJ, Santos RAS. Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 2005;38:499-507
36. Hase N. Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients. AU2002328494; 2008
37. Bohm M. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: Where do we stand now? Am J Cardiol 2007;100(Suppl):38J-44J
38. Weber MA. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol 2007;100(Suppl):45J- 52J
39. Venkata C, Ram MD. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008;121:656-663
40. Bohm P. Co-administration of an angiotensin II (ANG II) antagonist and an ACE inhibitor for treating congestive heart failure. NZ546884; 2008
41. Unger T. Rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol 2007;100(Suppl):25J-31J
42. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
43. Lakhdar R, Al-Mallah MH, Lanfear DE. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Cardiac Fail 2008;14:181-188
44. Messerli F. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009;53:468-470
45. Schindler C. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET. Ther Adv Cardiovasc Dis 2008;2:233-248
46. Coats AJS. Omapatrilat-the ups and downs of an exciting but complicated new drug. Int J Cardiol 2000;74:1-3 (Pubitemid 30347496)
47. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 2000;356:608-609 (Pubitemid 30627581)
48. Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep 2003;5:346-352 (Pubitemid 38898957)
49. Song JC, White M. Focus on omapatrilat. Formulary 2001;36:698-707
50. Feng L. Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor. KR20080075055; 2008
51. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use. Arch Intern Med 2004;164:910-913
52. Symvoulakis EK, Kyrmizakis DE, Drivas EI, et al. Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker-related angioedema: a neglected issue in daily practice in Greece. Eur J Gen Pract 2007;13:239-241
53. Tolerability and quality of life in ARB-treated patients. Am J Manag Care 2005;11:S392-4
54. Rüster C, Bondeva T, Franke S, et al. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol 2009;29:538-550
55. Yamamoto Y, Watari Y, Brydun A, et al. Role of the angiotensin II type 2 receptor in arterial remodelling after wire injury in mice. Hypertens Res 2008;31:1241-1249
56. Acosta E, Pena O, Naftolin F, et al. Angiotensin II induces apoptosis in human mural granulosa-lutein cells, but not in cumulus cells. Fertil Steril 2008. Epub (10.1016/j.fertnstert.2008.04.026)
57. Esteban V, Ruperez M, Vita JR, et al. Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl 2003;86:S33-8 (Pubitemid 37159625)
58. Waseda Y, Yasui M, Nishizawa Y, et al. Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respir Res 2008;9:43-51
59. Ferreira A, Raizada MK. Are we poised to target ACE2 for the next generation of antihypertensives? J Mol Med 2008;86:685-690
60. Sinisterra MRD. Process for the preparation of compounds of AT1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. WO2008052295; 2008
61. Azizi M. Direct renin inhibition: clinical pharmacology. J Mol Med 2008;86:647-654
62. Muller DN, Derer W, Dechend R. Aliskiren - mode of action and preclinical data. J Mol Med 2008;86:659-662
63. Hershey JC, Steiner B, Fischli W, Feuerstein G. Renin inhibitors: an antihypertensive strategy on the verge of reality. Drug Discov Today 2005;2:181-185 (Pubitemid 41488150)
64. Dockery BK, Bisognano JD. Direct renin inhibition: an analysis of possible benefits. Curr Hypertens Rep 2008;10:313-318
65. Athyros V, Mikhailidis DP, Kakafika AI. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007;8(5):529-535
66. Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 2008;121:265-271
67. Stanton A. Now that we have a direct renin inhibitor, what should we do with it? Curr Hypertens Rep 2008;10:194-200
68. Schefe JH, Unger T, Funke-Kaiser H. PLZF and the (pro)renin receptor. J Mol Med 2008;86:623-627
69. Blumenfeld JD, Sealey JE, Mann SJ, et al. β-adrenergic receptor blockade as a therapeutic approach to suppressing the renin-angiotensin- aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-459 (Pubitemid 29238406)
70. Takahashi S, Hori K, Shinbo M, et al. Isolation of human renin inhibitor from soybean: soyasaponin I is the novel human renin inhibitor in soybean. Biosci Biotech Biochem 2008;72:3232-3236
71. Baldwin JJ. 1-Acylamino-2-hydroxy-3-amino-arylalkanes as renin inhibitors. US2008293701; 2008
72. Ehara T. 3.5-Substituted piperidine compounds as renin inhibitors. KR20080086921; 2008
73. Herold P. 5-Amino-4-hydroxy-7- (imadazo[1,2-A] pyridin-6-ylmethyl)-8- methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension. CN101268074; 2008
74. Sedrani R. 4-Phenylpiperidine derivatives as renin inhibitors. US2008269255; 2008
75. Vincenzo T. Heterocyclic-substituted alkanamides useful as renin inhibitors. CN101171230; 2008;
76. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-1791 (Pubitemid 41579797)
77. Black HR. Evolving role of aldosterone blockers alone and in combination with angitensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: A review of mechanistic and clinical data. Am Heart J 2004;147:564-572 (Pubitemid 38900438)
78. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-545 (Pubitemid 39070505)
79. George J, Struthers AD. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin Pharmacother 2007;8:3053-3059 (Pubitemid 350285019)
80. Davis KL, Nappi JM. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. Clin Ther 2003;25:2647-2668 (Pubitemid 37510583)
81. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci 2007;113:267-278 (Pubitemid 47372685)
82. Chai W, Danser AHJ. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebergs Arch Pharmacol 2006;374:153-162
83. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717
84. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321 (Pubitemid 36384098)